Pneumococcal Conjugate Vaccine Clinical Trial
Official title:
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23vPS Vaccine
This study is to evaluate the safety, tolerability and immunogenicity of 13-valent pneumococcal Conjugate Vaccine in children with Sickle Cell Disease who have already been vaccinated with 23-valent polysaccharide vaccine. The study will measure the amount of antibodies (the proteins that fight off germs) produced by children with Sickle Cell Disease after they have been given the 13-valent pneumococcal vaccine between 6 and less than 18 years of age. They will be given the vaccination twice, each vaccination separated by approximately 6 months.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04401488 -
Paediatric Post Pneumococcal Conjugate Vaccine Nasopharyngeal Carriage Study
|
||
| Completed |
NCT00688870 -
Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan
|
Phase 3 | |
| Completed |
NCT03574389 -
A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children
|
Phase 3 | |
| Completed |
NCT01646398 -
A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older
|
Phase 3 | |
| Completed |
NCT00824850 -
Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort
|
Phase 2 | |
| Recruiting |
NCT04664569 -
National Bacterial Meningitis Study
|
||
| Recruiting |
NCT04664556 -
Invasive Pneumococcal Disease Study
|